Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Can J Cardiol. 2007 Feb;23(2):125-31.

The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.

Author information

  • University of British Columbia, Vancouver, Canada. jacairns@medd.med.ubc.ca

Abstract

There is strong evidence from randomized clinical trials that the highly selective cox-2 inhibitors (coxibs), compared with placebo, cause an excess of serious cardiovascular events that are not mitigated by low-dose acetylsalicylic acid. Both Health Canada and the Food and Drug Administration have concluded that the excess cardiovascular events may be a 'class effect' of all the nonsteroidal anti-inflammatory drugs (NSAIDs), including traditional NSAIDs (tNSAIDs) and coxibs, and now require appropriate black box labelling of all these agents. Celecoxib and lumiracoxib are the only coxibs remaining on the market in Canada. The prostanoid pathways, the roles of cox-1 and cox-2, as well as the inhibitory effects of acetylsalicylic acid, traditional tNSAIDs and the coxibs, are briefly reviewed. Current recommendations for the ongoing use of coxibs and the tNSAIDs are summarized.

PMID:
17311118
[PubMed - indexed for MEDLINE]
PMCID:
PMC2650648
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1)
Figure 2)
Figure 3)
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk